c-LEcta Signs Europe Sales and Distribution Agreement with VWR for DENARASE®
c-LEcta, a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma, signs a European sales and distribution agreement for its DENARASE ® with VWR, part of Avantor. The high quality and highly active nuclease enzyme offers more efficient solutions for the removal of genetic information carriers (nucleic acids; DNA and RNA) in biopharmaceutical processes to pharmaceutical manufacturers. The availability and distribution of DENARASE ® via VWR’s well established European channels harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market.
DENARASE® helps to remove nucleic acids from many applications of red biotechnology and molecular biology to be marketable and to comply with regulatory requirements under lucrative and more biocompatible conditions. It has proven to be robust under demanding process conditions and quantitatively removes interfering host cell DNA and RNA from fermentation batches, e.g. during the production of vaccines and biopharmaceuticals. The complete removal of nucleic acids from pharmaceutical products is a strict regulatory demand. Furthermore, the handling of process liquids (e.g. in filtration or chromatography) can be considerably simplified and the follow-up costs reduced to a competitive level. Therefore, DENARASE® is the ideal choice for pharmaceutical manufacturers to optimize process efficiencies and improve product recovery rates for the production of safe and compliant pharmaceutical products.
DENARASE® is manufactured using a patent protected production process based on the recombinant expression in an endotoxin-free Bacillus production host. The manufacturing process does avoid the use of raw material of animal origin and antibiotics and is run in full compliance with cGMP (current Good Manufacturing Practice) requirements.
"We are very pleased to announce our distribution agreement with VWR, part of Avantor, to provide yet even better services to our valued customers in Europe" says Cord von Limburg, Head of Sales at c-LEcta. "There is a substantial opportunity here to gain additional share in what is a highly dynamic market. By partnering with VWR we believe that the combination of our product innovation and their reputation for service and quality will further develop c-LEcta´s customer base.”
Based on this agreement, DENARASE® will now be available through vwr.com and all other regular VWR sales channels in Europe.
cometis AG for c-LEcta
Phone: +49 (0) 611 - 205855 – 22
Fax: +49 (0) 611 - 205855 – 66
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The O-RAN Alliance Announces New Board Members11.12.2018 14:00 | Pressemelding
The O-RAN Alliance announced today that Reliance Jio, TIM, and Verizon have joined the O-RAN board. “It’s encouraging to see the O-RAN Alliance off to such a strong start and gaining momentum as we welcome three new board members. It’s important that the wireless industry continues to come together to drive forward O-RAN’s goals for open networking, software, and virtualization in global wireless networks especially as 5G is closer than ever,” said Andre Fuetsch, Chairman of the O-RAN Alliance, President-AT&T Labs and CTO of AT&T. “This is a great opportunity for the Service Provider Industry as network, services and applications leverage cloud native platforms and the right time to fundamentally transform the RAN infrastructure and platforms. We look forward to working closely with the O-RAN Alliance in the acceleration and adoption of open, intelligent, and programmable RAN architectures that can clearly disrupt the building blocks of 5G and beyond,” said Mathew Oommen, President, Re
Seoul Semiconductor Wins Patent Litigation against Everlight in Germany and Is Awarded Statutory Litigation Costs11.12.2018 14:00 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it won a patent litigation against Everlight Electronics Co., Ltd. (“Everlight”) in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005233/en/ Seoul Semiconductor's Headquarters in Korea (Photo: Business Wire) The patent involved in this litigation relates to an LED package structure for thermal dissipation. Everlight purchased this patent from a U.S. company in 2017, and subsequently brought a patent lawsuit against Seoul in the Manheim Court of Germany. In December 2018, however, the Manheim Court ruled in favor of Seoul and ordered that Everlight, as the losing party, should bear the statutory costs of the court proceeding. In the United Kingdom, Seoul had already won a patent litigation against Everlight earlier this year. At that time, the UK Patent Court also ordered that Ever
Zodiac Appoints Derek Harrar CEO11.12.2018 14:00 | Pressemelding
Zodiac, a software vendor serving video service providers, announced today it has appointed Derek Harrar to serve as the Company’s Chief Executive Officer, effective immediately. Mr. Harrar has been on Zodiac’s board of directors since 2015, having being appointed at the time of One Equity Partners’ investment in the Company. “Derek’s considerable video industry operational and technology experience, rigorous execution and creativity are exactly what Zodiac needs for its next stage of growth, complementing the team we have put in place since our original investment,” said Andrew Dunn, Managing Director at One Equity Partners. Zodiac’s historic focus has been engineering software solutions for major video service providers in North America. This software experience, spanning a broad range of video technology permutations, is unique in the video distribution industry. More recently, Zodiac productized its carrier-grade cloud and client platform, enabling rapid and flexible deployment at
Quotient Sciences Conducts Integrated Translational Pharmaceutics® Program in U.S. with Druggability Technologies11.12.2018 13:00 | Pressemelding
Quotient Sciences, a leading drug development services organization, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceutics® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceutics program delivered from its U.S. operating facilities. Within the program of work, DRGT is accessing Quotient’s unique Translational Pharmaceutics platform. This involves the development of amorphous spray-dried formulations and GMP clinical trial manufacturing in Philadelphia followed by clinical dosing and taste assessment at Quotient’s clinical pharmacology unit in Miami. The program is fully adaptive, which will enable DRGT to optimize the drug product in response to emerging clinical data. Quotient will then seamlessly scale up the selected
The Brightline Initiative Announces Strategic Partnership with NetEase11.12.2018 13:00 | Pressemelding
The Brightline Initiative announced today that NetEase (网易) joined its coalition as first founding member from the Asia region to help address the growing challenges of strategy implementation leveraging on insight and learnings from Chinese technology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005409/en/ Brightline Initiative Announces Strategic Partnership with NetEase (Photo: Business Wire) Launched in early 2017, the Brightline™ Initiative is a coalition, led by the Project Management Institute together with leading global organizations, dedicated to helping executives bridge the expensive and unproductive gap between strategy design and delivery. Brightline focuses its work on three key areas: Thought and Practice Leadership, Networking and Capability Building. NetEase Hangzhou Research Institute Chief Executive Chen Gang said, “Historically NetEase has been paying close attention on strategy design
AMRA Receives U.S. FDA Clearance for AMRA® Profiler, a Magnetic Resonance Diagnostic Software Application Enabling Non-Invasive Evaluation of Body Composition11.12.2018 11:28 | Pressemelding
AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now available for use in a clinical setting in the US. AMRA® Profiler is indicated for use as a magnetic resonance (MR) diagnostic device for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements. AMRA is the first in the world to transform MR-images from a 6-minute whole-body MRI scan into 3D-volumetric fat and muscle measurements, enabling outstanding accuracy and precision when assessing volume and distribution of fat and muscles, as well as metabolic status. “We are delighted with the FDA’s decision. The challenges facing healthcare systems across the world are well-documented. Cost constraints, together with societal issues such as obesity and an aging population, are putting hospitals and private clinics under increasing pressure,” stated Eric Converse, CEO of